
ALPS Medical Breakthroughs ETF (SBIO)
SBIONYSEARCASS&CEquity
As of Nov 20, 2026 close
- Assets (AUM)
- $211.51M
- Expense ratio
- 0.50%
- Dividend yield
- -
- Holdings
- 107
- 52-week range
- $45.65$70.85
- Volume (live)
- -
- Avg. volume (3M)
- 27.14K
SBIO ETF Holdings: ALPS Medical Breakthroughs ETF
The largest positions with their portfolio weights, plus sector breakdown and geographic exposure for this Equity ETF. Analyze fund diversification and concentration.
Portfolio Allocations
Distribution breakdown by sector, asset type, and geographic region. Understand the fund's diversification strategy across markets and asset classes.
Loading chart...
Top 49 of 107 SBIO Holdings by Portfolio Weight
Holdings data last updated Oct 4, 2026. Ticker, name, asset type and portfolio weight for each position. Fund disclosures available to us list the largest 49 positions.
| # | Symbol | Name | Type | Weight |
|---|---|---|---|---|
| 1 | ![]() | CG Oncology, Inc. | Stock | 3.88% |
| 2 | ![]() | Oruka Therapeutics, Inc. | Stock | 3.64% |
| 3 | ![]() | Travere Therapeutics, Inc. | Stock | 3.49% |
| 4 | ![]() | Dianthus Therapeutics Inc. | Stock | 3.43% |
| 5 | ![]() | Definium Therapeutics, Inc. | Stock | 3.27% |
| 6 | ![]() | Xenon Pharmaceuticals Inc | Stock | 3.25% |
| 7 | ![]() | Veradermics, Incorporated | Stock | 3.17% |
| 8 | ![]() | Edgewise Therapeutics, Inc. | Stock | 2.92% |
| 9 | ![]() | ACADIA Pharmaceuticals Inc | Stock | 2.74% |
| 10 | ![]() | Relay Therapeutics, Inc. | Stock | 2.70% |
| 11 | ![]() | IDEAYA Biosciences, Inc. | Stock | 2.34% |
| 12 | ![]() | Amylyx Pharmaceuticals, Inc. | Stock | 2.27% |
| 13 | ![]() | Denali Therapeutics Inc. | Stock | 2.08% |
| 14 | ![]() | Tarsus Pharmaceuticals, Inc. | Stock | 2.08% |
| 15 | ![]() | Dyne Therapeutics, Inc. | Stock | 1.85% |
| 16 | ![]() | MBX Biosciences, Inc. | Stock | 1.83% |
| 17 | ![]() | Celldex Therapeutics Inc | Stock | 1.81% |
| 18 | ![]() | NewAmsterdam Pharma Company N.V. | Stock | 1.80% |
| 19 | ![]() | Zai Lab Limited | Stock | 1.78% |
| 20 | ![]() | Structure Therapeutics Inc. American Depositary Shares | Stock | 1.66% |
| 21 | ![]() | Immunome, Inc | Stock | 1.62% |
| 22 | ![]() | Disc Medicine, Inc. | Stock | 1.61% |
| 23 | ![]() | SELLAS Life Sciences Group, Inc. | Stock | 1.54% |
| 24 | ![]() | Mineralys Therapeutics Inc. Common Stock | Stock | 1.53% |
| 25 | ![]() | Vera Therapeutics Inc | Stock | 1.45% |
| 26 | ![]() | Viridian Therapeutics Inc | Stock | 1.44% |
| 27 | ![]() | Nektar Therapeutics | Stock | 1.35% |
| 28 | ![]() | Sarepta Therapeutics, Inc | Stock | 1.31% |
| 29 | ![]() | Palvella Therapeutics, Inc | Stock | 1.30% |
| 30 | ![]() | Generate Biomedicines, Inc. Common Stock | Stock | 1.24% |
| 31 | ![]() | BioCryst Pharmaceuticals Inc | Stock | 1.24% |
| 32 | ![]() | Rapport Therapeutics, Inc. Common Stock | Stock | 1.22% |
| 33 | ![]() | Vericel Corporation | Stock | 1.21% |
| 34 | ![]() | Nuvation Bio Inc | Stock | 1.21% |
| 35 | ![]() | Zenas BioPharma, Inc. Common Stock | Stock | 1.21% |
| 36 | ![]() | Agios Pharmaceuticals, Inc | Stock | 1.17% |
| 37 | ![]() | COMPASS Pathways plc | Stock | 1.11% |
| 38 | GLPG | Galapagos NV ADR | Stock | 1.09% |
| 39 | ![]() | Xencor, Inc | Stock | 1.05% |
| 40 | ![]() | Stoke Therapeutics, Inc | Stock | 1.05% |
| 41 | ![]() | Kailera Therapeutics, Inc. Common Stock | Stock | 1.04% |
| 42 | ![]() | Immunocore Holdings plc | Stock | 0.97% |
| 43 | ![]() | BCAX | Stock | 0.89% |
| 44 | ![]() | Taysha Gene Therapies, Inc | Stock | 0.87% |
| 45 | ![]() | Maze Therapeutics, Inc. Common Stock | Stock | 0.80% |
| 46 | ![]() | ArriVent BioPharma, Inc. Common Stock | Stock | 0.78% |
| 47 | ![]() | LB Pharmaceuticals Inc Common Stock | Stock | 0.74% |
| 48 | ![]() | Seaport Therapeutics, Inc. Common Stock | Stock | 0.74% |
| 49 | ![]() | Vor Biopharma Inc | Stock | 0.72% |
Source: Fund holdings disclosures. Last updated Oct 4, 2026. Data sources and methodology
Frequently Asked Questions About ALPS Medical Breakthroughs ETF Holdings
What are the top holdings in SBIO?
In holdings data last updated Oct 4, 2026, SBIO's largest holdings are CG Oncology, Inc. (CGON) at 3.88%, Oruka Therapeutics, Inc. (ORKA) at 3.64%, Travere Therapeutics, Inc. (TVTX) at 3.49%, Dianthus Therapeutics Inc. (DNTH) at 3.43% and Definium Therapeutics, Inc. (DFTX) at 3.27%. Together these 5 positions make up 17.7% of the fund. SBIO holds 107 securities in all; the holdings data lists the top 49 by weight.
How concentrated is SBIO's portfolio?
In holdings data last updated Oct 4, 2026, the 10 largest of SBIO's 107 positions make up 32.5% of assets. The largest single position is CG Oncology, Inc. (CGON) at 3.88%. The top 49 listed positions add up to 85.5%, so the remaining 58 holdings share 14.5%. Its largest sector, Healthcare, is 100.0% of the portfolio.
What is SBIO's sector allocation?
In holdings data last updated Oct 4, 2026, SBIO's largest sector weights are Healthcare (100.0%), together 100.0% of the portfolio. It has exposure to 1 sector in total.
What countries does SBIO invest in?
In holdings data last updated Oct 4, 2026, 91.5% of SBIO's portfolio is invested in the United States, followed by Netherlands (3.5%), Canada (2.0%) and Switzerland (1.6%). SBIO has exposure to 6 countries in total. By asset type the fund is 99.8% stocks and 0.2% cash.















































